161 related articles for article (PubMed ID: 27415417)
21. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
[TBL] [Abstract][Full Text] [Related]
22. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Durot E; Kanagaratnam L; Zanwar S; Kastritis E; D'Sa S; Garcia-Sanz R; Tomowiak C; Hivert B; Toussaint E; Protin C; Abeykoon JP; Guerrero-Garcia T; Itchaki G; Vos JM; Michallet AS; Godet S; Dupuis J; Leprêtre S; Bomsztyk J; Morel P; Leblond V; Treon SP; Dimopoulos MA; Kapoor P; Delmer A; Castillo JJ
Haematologica; 2021 Nov; 106(11):2940-2946. PubMed ID: 33179472
[TBL] [Abstract][Full Text] [Related]
23. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Hwang HS; Yoon DH; Suh C; Huh J
Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
[TBL] [Abstract][Full Text] [Related]
24. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
[TBL] [Abstract][Full Text] [Related]
25. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Souchet L; Levy V; Ouzegdouh M; Tamburini J; Delmer A; Dupuis J; Le Gouill S; Pégourié-Bandelier B; Tournilhac O; Boubaya M; Vargaftig J; Choquet S; Leblond V;
Am J Hematol; 2016 Aug; 91(8):782-6. PubMed ID: 27135784
[TBL] [Abstract][Full Text] [Related]
27. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
28. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
29. Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
Kyle RA; Benson JT; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Melton LJ; Rajkumar SV
Blood; 2012 May; 119(19):4462-6. PubMed ID: 22451426
[TBL] [Abstract][Full Text] [Related]
30. Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?
Ling S; Joshua DE; Gibson J; Young G; Iland H; Watson G; Ho PJ
Am J Hematol; 2006 Feb; 81(2):110-4. PubMed ID: 16432856
[TBL] [Abstract][Full Text] [Related]
31. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time.
Chang ST; Lu YH; Lu CL; Weng SF; Lin SH; Kuo SY; Chuang YT; Takeuchi K; Ohshima K; Chuang SS
J Clin Pathol; 2014 Apr; 67(4):326-32. PubMed ID: 24218026
[TBL] [Abstract][Full Text] [Related]
33. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
34. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
35. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
36. Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.
Morra E; Varettoni M; Tedeschi A; Arcaini L; Ricci F; Pascutto C; Rattotti S; Vismara E; Paris L; Cazzola M
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):700-3. PubMed ID: 24070824
[TBL] [Abstract][Full Text] [Related]
37. Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report.
Nasir SA; Pandya D; Wojkiewicz S; Khandpur B; Downes E; Pathare P; Frank R
Cureus; 2022 Dec; 14(12):e32403. PubMed ID: 36636536
[TBL] [Abstract][Full Text] [Related]
38. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.
Bledsoe JR; Redd RA; Hasserjian RP; Soumerai JD; Nishino HT; Boyer DF; Ferry JA; Zukerberg LR; Harris NL; Abramson JS; Sohani AR
Am J Hematol; 2016 Oct; 91(10):E436-41. PubMed ID: 27419920
[TBL] [Abstract][Full Text] [Related]
39. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
40. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]